<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525707</url>
  </required_header>
  <id_info>
    <org_study_id>AC-051-306</org_study_id>
    <nct_id>NCT00525707</nct_id>
  </id_info>
  <brief_title>Tezosentan in Acute Heart Failure</brief_title>
  <acronym>VERITAS 1</acronym>
  <official_title>Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized patients with acute heart failure will be stratified based on the presence or
      absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the
      first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of
      the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days
      after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up
      period of 5 months for vital status.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of death or worsening heart failure</measure>
    <time_frame>7 days following study drug initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect on patient's dyspnea assessment, measured using a visual analog scale</measure>
    <time_frame>Over first 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">735</enrollment>
  <condition>Acute Heart Failure</condition>
  <condition>Acute Decompensation of Chronic Heart Failure</condition>
  <condition>New Onset of Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tezosentan</intervention_name>
    <description>tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years of age or older.

          2. Male or non-breast-feeding, non-pregnant female (only females who are post menopausal,
             surgically sterile or practicing a reliable method of contraception).

          3. Acute heart failure (ischemic or non-ischemic).

          4. Randomization within 24 hours of hospitalization (including emergency room stay) for
             acute heart failure.

          5. Dyspnea at rest as assessed by the patient and breathing rate ³ 24/min (measured
             during 60 seconds).

          6. At least two out of the following four criteria: · elevated BNP or N terminal pro-BNP
             (more than three times the upper limit of normal for the site) in patients not treated
             with nesiritide,· clinical evidence of pulmonary congestion/edema (e.g., rales or
             crackles more than a third above bases),· evidence of pulmonary congestion on chest
             X-ray, · left ventricular systolic dysfunction (EF &lt; 40% or wall motion index £ 1.2
             within 12 months prior to randomization).

          7. Patients in need of i.v. therapy for acute heart failure and who have received at
             least one dose of i.v. diuretic within 24 hours prior to study drug initiation (last
             bolus dose must have been more than 2 hours prior to study drug initiation).

          8. Written informed consent.

        Exclusion Criteria:

        Criteria only for patients hemodynamically monitored:

          1. Baseline cardiac index &gt; 2.5 l/min/m2 and/or PCWP &lt; 20 mmHg within 6 hours prior to
             study drug initiation.

             Criteria for all patients:

          2. Patients not receiving i.v. vasodilators (e.g., nitrates, nitroprusside, nesiritide)
             at baseline: supine systolic blood pressure &lt; 100 mmHg. Patients receiving i.v.
             vasodilators (e.g., nitrates, nitroprusside, nesiritide) at baseline: supine systolic
             blood pressure &lt; 120 mmHg.

          3. Cardiogenic shock within the last 48 hours or evidence of volume depletion.

          4. Ongoing myocardial ischaemia, coronary revascularisation procedure (PCI or CABG)
             during current admission or planned revascularisation.

          5. ST-segment elevation myocardial infarction or administration of thrombolytic therapy.

          6. Baseline creatinine ≥ 2.5 mg/dl (221 mmol/l).

          7. Baseline hemoglobin &lt; 10 g/dl or a hematocrit &lt; 30%.

          8. Hemodialysis, ultrafiltration or peritoneal dialysis within the last 7 days.

          9. Heart failure due to active myocarditis, obstructive hypertrophic cardiomyopathy,
             congenital heart disease, restrictive cardiomyopathy or constrictive pericarditis.
             Heart failure caused by valvular disease.

         10. Acute heart failure associated with uncontrolled hemodynamically relevant atrial
             fibrillation/flutter or ventricular rhythm disturbances.

         11. Acute heart failure secondary to clinical evidence of digoxin toxicity or any other
             drug-related toxicity.

         12. Significant chronic and/or acute lung disease that might interfere with the ability to
             interpret the dyspnea assessments or hemodynamic measurements (e.g., severe chronic
             obstructive pulmonary disease or acute pneumonia).

         13. Mechanical circulatory or ventilatory support. Prior CPAP use is allowed, if
             discontinued at least 2 hours prior to study drug initiation.

         14. Acute systemic infection/sepsis or other illness with a life expectancy less than 30
             days.

         15. Coronary artery bypass graft, or other cardiac surgery, or major non-cardiac surgery
             within the last 30 days.

         16. Patients who received another investigational drug within 30 days prior to
             randomization.

         17. Re-randomization in the current study.

         18. Any factors that might interfere with the study conduct or interpretation of the
             results such as known drug or alcohol dependence.

         19. Concomitant treatment with cyclosporin A or tacrolimus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Heart Failure and Transplant Service, Palo Alto VA Health Care System, Cardiology Section</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver VAMC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital at Alledgheny General, Division of Cardiology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cardiovascular Consultants</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danville Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates, Bellebue</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH University of Vienna, Abt. Medizinische Kardiologie</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Amt Sygehus</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Ambroise Pare, Service de Cardiologie</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Failure clinic C.H. Dubos</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg, Hopital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil, Cardiologie A</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik I, Universitatsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Virchow-Klinikum, Medizinishe Klinik mit Schwerpunkt Kardiologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg-August-Universitat Gottingen, Zentrum fur Innere Med</name>
      <address>
        <city>Gottingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Cardiology, University of Athens, Alexandra Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Hospital</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nazareth Hospital EMMS</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Kardiologii i Chorob Wewnetrznych, Samodzielny Publiczny Szpital</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chorob Serca, Akademia Medyczna w Gdansku</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I Klinika Kardiolgii, Collegium Medicum UJ</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology College, College of Medicine of Jagellonian University</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kategra I Klinika Kardiolgii AM</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio Centro Ticino, Servizio Cardiovasculare</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Kingston Upon Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scunthorpe General Hospital</name>
      <address>
        <city>Scunthorpe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <disposition_first_submitted>February 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <keyword>acute heart failure</keyword>
  <keyword>Actelion</keyword>
  <keyword>tezosentan</keyword>
  <keyword>acute decompensation of chronic heart failure</keyword>
  <keyword>New onset of heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tezosentan</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

